Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Glenmark Acquires and Launches Acetylcysteine Injection | Contract Pharma

What are you searching for?

Sign in
Breaking News

Glenmark Acquires and Launches Acetylcysteine Injection

Expands its injectable portfolio in the U.S. market.

Glenmark Pharmaceuticals Inc. USA has acquired and launched Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials, which are expected to deliver the same therapeutic effect as the branded drug product Acetadote Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials of Cumberland Pharmaceuticals Inc.

Acetylcysteine, a widely used therapeutic agent, is employed to treat acetaminophen overdose and as a mucolytic agent in managing respiratory conditions.

Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA Inc.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, remarked, “We are excited to announce the acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. This is a great addition to our injectable portfolio in the U.S. market as we continue to drive growth for the hospital segment.”

More Glenmark News

In February, Glenmark launched Latanoprost Ophthalmic Solution, a 0.005% (0.05 mg/mL) ophthalmic solution.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics